作者: McLean, Nev ; Liang, Jun ; Kleinheinz, Tracy ; Friedman, Lori ; Nannini, Michelle ; Li, Jun ; Liao, Jiangpeng ; Vinogradova, Maia ; Blake, Robert A ; Ray, Nick ; Zhang, Birong ; Mody, Vidhi ; Labadie, Sharada ; Kiefer, James R ; Ran, Yingqing ; Chang, Jae ; Goodacre, Simon ; Hartman, Steven J ; Wang, Tao ; Wai, John ; Zbieg, Jason R ; Sampath, Deepak ; Zhong, Yu ; Ortwine, Daniel F ; Yeap, Kuen ; Metcalfe, Ciara ; Roussel, Fabien ; Zheng, Xiaoping ; Rei Ingalla, Ellen ; Lai, Tommy ; Wang, Xiaojing ; Sambrone, Amy

Fulvestrant is an FDA-approved drug with a dual mechanism of action (MOA), acting as a full antagonist and degrader of the estrogen receptor protein. A significant limitation of fulvestrant is the dosing regimen required for efficacy. Due to its high lipophilicity and poor pharmacokinetic profile, fulvestrant needs to be administered through intramuscular injections which leads to injection site soreness. This route of administration also limits the dose and target occupancy in patients. We envisioned a best-in-class molecule that would function with the same dual MOA as fulvestrant, but with improved physicochemical properties and would be orally bioavailable. Herein we report our progress toward that goal, resulting in a new lead GNE-502 which addressed some of the liabilities of our previously reported lead molecule GNE-149.

2020-06-11·ACS Medicinal Chemistry Letters3区 · 医学

Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer

3区 · 医学

Article

作者: Vinogradova, Maia ; Yeap, Kuen ; Chang, Jae ; Friedman, Lori S. ; Mody, Vidhi ; Roussel, Fabien ; Nannini, Michelle ; Otwine, Daniel ; Zheng, Xiaoping ; Liang, Jun ; Labadie, Sharada ; Wai, John ; Blake, Robert ; Zhang, Birong ; Liao, Jiangpeng ; Wang, Tao ; Ran, Yingqing ; Kiefer, James R. ; Sampath, Deepak ; Goodacre, Simon ; Li, Jun ; Wang, Xiaojing ; Ingalla, Ellen Rei ; Young, Amy ; Ray, Nick ; Hartman, Steven ; Lai, Kwong Wah ; McLean, Neville ; Zhong, Yu ; Kleinheinz, Tracy ; Zbieg, Jason ; Sambrone, Amy ; Metcalfe, Ciara

Estrogen receptor alpha (ERα) is a well-validated drug target for ER-positive (ER+) breast cancer. Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability. Thus, we envisioned a "best-in-class" molecule with the same dual mechanisms as fulvestrant, but with significant oral exposure. Through lead optimization, we discovered a tool molecule 12 (GNE-149) with improved degradation and antiproliferative activity in both MCF7 and T47D cells. To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue. Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.

100 项与 GNE-149 相关的药物交易

登录后查看更多信息